Drug
Ompekimig clinical trials
Also written PF-07264660.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ompekimig is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisActive, not recruitingPhase 2PfizerNCT05995964Written as PF-07264660
- A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult ParticipantsCompletedPhase 1PfizerNCT06712082Written as PF-07264660
- A Preliminary Study to Evaluate PF-07264660 in Healthy ParticipantsCompletedPhase 1PfizerNCT05496738Written as PF-07264660 intravenous single ascending dose
Codes
What other systems call ompekimig · ClinicalTrials.gg INT015525
- UNII (FDA) 7S9F79AD9ZOMPEKIMIGOne source FDA
- NCI Thesaurus C211744OmpekimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7S9F79AD9Z | OMPEKIMIG | One source FDA |
| NCI Thesaurus | C211744 | Ompekimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.